OpenLobby.EU
Explore

Médecins Sans Frontières International

MSF International

MSF is an independent medical humanitarian organization delivering emergency aid to people affected by armed conflict, epidemics, natural disasters and healthcare exclusion.

Lobbying Activity

Meeting with Henrike Trautmann (Director Middle East, North Africa and the Gulf) and Norwegian Refugee Council Europe

13 Jan 2026 · Perspectives in Gaza and the West Bank.

Meeting with Lora Borissova (Cabinet of Commissioner Hadja Lahbib)

12 Jan 2026 · • Humanitarian crisis • Middle East • Israel • NGO Registration

Meeting with Salvador Franca (Cabinet of High Representative/ Vice-President Kaja Kallas) and Norwegian Refugee Council Europe and International Rescue Committee Inc

8 Dec 2025 · Sudan

Meeting with Valérie Hayer (Member of the European Parliament) and Google and

19 Nov 2025 · IA

Meeting with Corinna Ullrich (Director Migration and Home Affairs) and International Federation of Red Cross and Red Crescent Societies and

6 Nov 2025 · Meeting between the European Commission and civil society representatives active in search and rescue activities.

Meeting with Birgit Sippel (Member of the European Parliament, Rapporteur) and Sea-Watch e.V.

5 Nov 2025 · Facilitation Directive

Meeting with Rainer Becker (Director Health and Food Safety)

20 Oct 2025 · Exchange of views on Access to Medicines

Meeting with Kathleen Van Brempt (Member of the European Parliament)

15 Oct 2025 · NGOs and situation on the ground in Palestine

Meeting with Hilde Vautmans (Member of the European Parliament)

13 Oct 2025 · Gaza

Meeting with Sandro Ruotolo (Member of the European Parliament)

24 Sept 2025 · Humanitarian crisis in Gaza

Meeting with Hadja Lahbib (Commissioner) and

23 Sept 2025 · • Humanitarian crises • Middle East • Sudan

Meeting with Birgit Sippel (Member of the European Parliament)

15 Sept 2025 · Delegation visit to the Closed Controlled Access Centre on Kos

Meeting with Lora Borissova (Cabinet of Commissioner Hadja Lahbib)

2 Sept 2025 · • Humanitarian crises • Middle East

Meeting with Lynn Boylan (Member of the European Parliament, Delegation chair)

16 Jul 2025 · MSF's work in Gaza

Meeting with Sirpa Pietikäinen (Member of the European Parliament)

3 Jul 2025 · Gaza

Meeting with Grigorios Delavekouras (Cabinet of Commissioner Magnus Brunner)

24 Jun 2025 · Discussion on the situation at the Polish-Belorussian border

Meeting with Beate Gminder (Director-General Migration and Home Affairs) and Human Rights Watch and OXFAM INTERNATIONAL EU ADVOCACY OFFICE

24 Jun 2025 · Flash report: Meeting with Human Rights Watch, Oxfam, and Doctors Without Borders/MSF on the situation at PL-BY border

Meeting with Mélissa Camara (Member of the European Parliament, Shadow rapporteur)

6 Jun 2025 · Reglement retour

Meeting with Hadja Lahbib (Commissioner) and

13 May 2025 · • Humanitarian Crisis • Humanitarian aid

Meeting with Cecile Billaux (Head of Unit Directorate-General for International Partnerships)

2 Apr 2025 · Exchange on the ongoing developments on the Fragility & Humanitarian Approach for Gavi 6.0 2026-2030

Meeting with Birgit Sippel (Member of the European Parliament, Rapporteur) and Amnesty International Limited and

17 Mar 2025 · Facilitation directive; entry-exit-system

Meeting with Silvia Michelini (Director Migration and Home Affairs) and Amnesty International Limited and

13 Mar 2025 · Discussion on the implementation of the Pact on Migration and Asylum in Italie

Meeting with Hans Das (Deputy Director-General European Civil Protection and Humanitarian Aid Operations)

12 Mar 2025 · Briefing on the situation in Sudan

Meeting with Sibylle Bikar (Cabinet of High Representative/ Vice-President Kaja Kallas)

14 Feb 2025 · Introductory meeting, MSF presented the main priorities for 2025.

Meeting with Zacharias Giakoumis (Head of Unit European Civil Protection and Humanitarian Aid Operations)

31 Jan 2025 · MSF and Commission exchanged views on the upcoming EHF 2025 (19-20 May 2025). The Commission outlined the concept behind the EHF 2025, its key themes (fragility and humanitarian diplomacy) and envisaged structure.

Meeting with Kim-Tobias Eling (Cabinet of Commissioner Janez Lenarčič)

15 Nov 2024 · Current humanitarian issues

Meeting with Sigrid Friis (Member of the European Parliament)

29 Oct 2024 · COP 29

Meeting with Tineke Strik (Member of the European Parliament) and Amnesty International Limited and

16 Oct 2024 · LIBE Civil Society Meeting

Meeting with Daniel Freund (Member of the European Parliament) and Amnesty International Limited and

16 Oct 2024 · Cooperation on LIBE related matters

Meeting with Rasmus Nordqvist (Member of the European Parliament)

15 Oct 2024 · Introduktionsmøde med Médecins Sans Frontières (MSF) OB

Meeting with Marco Tarquinio (Member of the European Parliament)

1 Oct 2024 · MSF work

Meeting with Beate Gminder (Acting Director-General Migration and Home Affairs)

26 Mar 2024 · discussion on the EU migration report 'Death, despair and destitution: the human costs of the EU's migration policies'

Meeting with Francisco Fontan Pardo (Cabinet of High Representative Josep Borrell Fontelles)

1 Mar 2024 · The discussion was on humanitarian situation of Gaza and Sudan

Meeting with Janez Lenarčič (Commissioner) and

1 Mar 2024 · Humanitarian crises in Gaza and Sudan

Meeting with Erik Marquardt (Member of the European Parliament, Shadow rapporteur) and European Digital Rights and

13 Feb 2024 · Facilitators Package - stakeholders’ consultation meeting

Meeting with Maurits-Jan Prinz (Cabinet of Commissioner Thierry Breton), Maurits-Jan Prinz (Cabinet of Commissioner Thierry Breton)

10 Jan 2024 · EU Compulsory Licensing

Meeting with Birgit Sippel (Member of the European Parliament, Rapporteur)

19 Oct 2023 · Migration Situation in Member States (staff level)

Meeting with Catherine Amalric (Member of the European Parliament, Shadow rapporteur) and European Social Insurance Platform AISBL

9 Oct 2023 · Reform of the EU pharmaceutical legislation

Meeting with Helmut Scholz (Member of the European Parliament, Rapporteur) and Stichting Health Action International

5 Oct 2023 · Compulsory licenses

Meeting with Helmut Scholz (Member of the European Parliament, Rapporteur) and Stichting Health Action International and Drugs for Neglected Diseases initiative

4 Oct 2023 · Compulsory licenses

Meeting with Camilo Villarino (Cabinet of High Representative Josep Borrell Fontelles)

25 Jul 2023 · The discussion was on current development in East Africa

Meeting with Kim-Tobias Eling (Cabinet of Commissioner Janez Lenarčič)

11 Jul 2023 · Response to major humanitarian crises

Meeting with Margrete Auken (Member of the European Parliament, Shadow rapporteur)

6 Jun 2023 · Pharma legislation

Meeting with Ilan De Basso (Member of the European Parliament) and Save the Children Europe and

30 May 2023 · Möte

Meeting with Maurits-Jan Prinz (Cabinet of Commissioner Thierry Breton)

23 Jan 2023 · Intellectual property framework

Meeting with Kim-Tobias Eling (Cabinet of Commissioner Janez Lenarčič)

11 Nov 2022 · Global public health; emergency medical response in major humanitarian crises

Meeting with Renaud Savignat (Cabinet of Commissioner Jutta Urpilainen) and OXFAM INTERNATIONAL EU ADVOCACY OFFICE and

9 Nov 2022 · Global Health Strategy

Response to EU strategic Framework for Global Health

16 Sept 2022

Médecins sans Frontières (MSF) call for evidence for the EU Global Health Strategy 2022. To be successful in meeting the needs of the poorest and most marginalised people, the European Union Global Health Strategy (EUGHS) must be: a) needs-based, b) rooted on principles of equity and inclusion, c) include transparency and accountability across all areas. The EUGHS should also be an opportunity for the EU to reaffirm its position in the defence of sexual and reproductive health rights (SRHR) globally, including by ensuring equitable access to SRHR-related health services and products. In the attached call for evidence, MSF provides specific recommendations along with supporting reports and analysis on: (1.2) how to improve health systems strengthening adapted to the specificities of each situation; (1.3) how to include and develop “community systems for health”; (1.4) how to ensure that Universal Health Coverage include both long-term and immediate health needs. Subsequent guidance addresses: (1.5) the need to ensure independent and unhindered humanitarian access in health emergencies, conflict situations and assistance to marginalised population groups; (1.6) health needs of ‘fragile and conflict-affected states’; (1.7) addressing the health consequences of climate change. The following submission includes a specific chapter on the inclusion of priorities on pandemic prevention, preparedness and response (PPR) in the EUGHS. The latter provides recommendations on: (2.1) PPR governance and priority focus; (2.2) equity; (2.3), liability; (2.4) and transparency and access to technology. In line with MSF and MSF Access campaign's work, we aim to highlight the need for the EUGHS to reshape the system of medical innovation in order to provide equitable access to health products and services. In doing so, we propose concrete recommendations and a review of the current needs in: (3.1) research, innovation and intellectual property rights, with a concrete focus on the situation of antimicrobial resistance; and to ensure a (3.2) diversified production. In a final section, MSF draws attention to the need for sustainable and equitable financing for global health. In order to ensure access to health services and tools, MSF provides recommendations on: (4.1) reducing out-of-pocket expenditure; (4.2) PPR financing and governance; (4.3) enhanced international financial support for health systems in low and middle-income countries; (4.4) reporting and monitoring of the EUGHS. MSF hopes that this comprehensive document on our positions, priorities and recommendations for the EUGHS will be useful to policy makers and other global health actors.
Read full response

Meeting with Kim-Tobias Eling (Cabinet of Commissioner Janez Lenarčič)

22 Jul 2022 · safety and security of humanitarian workers

Meeting with Tineke Strik (Member of the European Parliament)

12 Jul 2022 · Libya and asylum

Meeting with Renaud Savignat (Cabinet of Commissioner Jutta Urpilainen)

7 Jul 2022 · Access to Covid tools and Global Health issues

Meeting with Maurits-Jan Prinz (Cabinet of Commissioner Thierry Breton)

7 Jul 2022 · Task force on vaccine production and initiatives in Africa

Meeting with Sara Cerdas (Member of the European Parliament)

1 Jul 2022 · COVAX and the COVI Committee

Meeting with Caroline Boeshertz (Cabinet of Executive Vice-President Valdis Dombrovskis), Kevin Keary (Cabinet of Executive Vice-President Valdis Dombrovskis)

3 May 2022 · tbc

Meeting with Caroline Boeshertz (Cabinet of Executive Vice-President Valdis Dombrovskis)

3 May 2022 · TRIPS

MSF Urges EU to Reform Patent Licensing for Medicine Access

29 Apr 2022
Topic — A consultation on standardizing and improving compulsory patent licensing procedures across the EU.
Message — MSF recommends expedited procedures and automatic waivers of data exclusivity for public health needs. They also suggest a coordinated regional approach to improve production and supply.12
Why — This would simplify the production and importation of affordable generic medicines globally.3
Impact — Pharmaceutical companies would lose their exclusive control over clinical data and market protection.4
Read full response

Response to Unitary Supplementary Protection Certificates (SPC) – creation and granting procedure

5 Apr 2022

Médecins Sans Frontières (MSF) recently published research in a peer-reviewed journal (attached) on supplementary protection certificates and their impact on access to medicines in Europe.1 The study examines sales revenue of and R&D investments in a number of lifesaving medicines (sofosbuvir, trastuzumab, and imatinib). The research indicates that the EU Supplementary Protection Certificate (SPC) regime may be based on a false premise that companies need longer exclusivity periods to compensate for the ‘loss’ of a period of effective intellectual-property protection during the market approval process, to enable them to recover R&D investments. The higher prices of these three medicines due to SPCs, which are associated with delays in supplies and competition of more affordable generic-medicines, appear to be an unnecessary and unjustifiable cost for society, both financially and socially. The SPC system can ultimately cause unnecessary suffering and/or death as healthcare systems or people are unable to afford essential medicines. MSF’s findings echoes other literature challenging the claim by pharmaceutical industry that the additional years granted through SPC is necessary to recoup the R&D investment. The evidence provided in MSF’s study suggests the need for a thorough assessment of the assumptions underpinning the SPC system. Moreover, the obstacles to obtaining pharmaceutical companies’ actual R&D cost data demonstrates the need for greater transparency to enable public scrutiny of healthcare expenditures. In the COVID-19 pandemic, MSF has observed again how SPC, alongside patents, could delay access to affordable medicines. Baricitinib, the oral treatment for COVID-19 recently recommended by WHO, has been granted SPC in several EU member states,2 prolonging the exclusivity of the originator company till at least 2032, while the primary patent expires in 2029. The originator company has priced this medicine several hundred times more than the current available generic prices and the estimated cost-based price estimation, based on a research conducted by scholars in Harvard University.3 MSF’s earlier findings and the present evidence in the pandemic raise questions as to the public benefit of granting SPCs on medicines altogether, and at a minimum, call for fundamental reform to the system and the way SPCs are granted. The conflation of the notions of time and cost in the granting of SPCs appears to be particularly problematic. The European Commission’s own evaluation that SPCs are needed as an incentive or reward for innovation is unconvincing. The evaluation’s dataset is missing and uses questionable methodological assumptions. MSF is therefore not supportive of the proposed policy options for a harmonisation of the SPC system in the EU, as this does not address the questionable basis on which SPCs are granted nor its negative social and health impact. The granting of SPCs on medicines should be reconsidered in light of its negative impact on access to medicines for people and healthcare systems. 1 Hu, Y., Eynikel, D., Boulet, P. et al. Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib. J of Pharm Policy and Pract 13, 1 (2020). https://doi.org/10.1186/s40545-019-0198-6 2 SPC on bariticinib has been identified in at least France, Ireland and Sweden. See: https://www.ipoi.gov.ie/en/ip-search-tools/patents-search/spc-database-snapshot/; France: https://data.inpi.fr/brevets/FR17C0005, and Sweden: https://tc.prv.se/spd/spcsearch?spcnummer=&patentnummer=EP2288610&substans=&innehavare=&lakemedelsnummer=&giltighetstidfrom=&giltighetstidtom=&tidnrtyp=&tidar_from=&tidnr_from=&tidar_tom=&tidnr_tom=&lang=en&hits=true&tab=4 3 Melissa Barber, Dzintars Gotham, ‘Estimated cost-based generic prices of baricitinib’, 2022, available at: https://scholar.harvard.edu/files/melissabarber/files/estimated_cost-based_generic_prices_for_baricitinib.
Read full response

Meeting with Raül Hernández Sagrera (Cabinet of Commissioner Ylva Johansson)

29 Nov 2021 · situation at EU Eastern borders

Meeting with Valdis Dombrovskis (Executive Vice-President)

18 Nov 2021 · Global access to COVID-19 vaccines and therapeutics

Meeting with Kim-Tobias Eling (Cabinet of Commissioner Janez Lenarčič)

15 Nov 2021 · Current humanitarian crises

Meeting with Caroline Boeshertz (Cabinet of Executive Vice-President Valdis Dombrovskis) and Human Rights Watch and Stichting Health Action International

7 Oct 2021 · COVID Vaccines

Meeting with Caroline Boeshertz (Cabinet of Executive Vice-President Valdis Dombrovskis), Cristina Rueda Catry (Cabinet of Executive Vice-President Valdis Dombrovskis) and

3 Jun 2021 · Trade in relation to COVID-related technologies

Response to Evaluation and revision of the general pharmaceutical legislation

27 Apr 2021

Médecins Sans Frontières (MSF) welcomes the European Commission’s ambition to ensure access to affordable medical tools. Beyond evaluating and revising the pharmaceuticals legislation, the Commission should take a comprehensive approach to revising the EU’s intellectual property (IP) and research and development (R&D) legislation and policies to meet this ambition. The EU should take the following actions to improve the legislation: 1. Include transparency conditions for market approval A lack of transparency impedes independent analysis to objectively evaluate and improve the effectiveness of pharmaceutical policies and practices. The EU should: •At the stage of market approval, require companies to publicly disclose the costs of R&D and manufacturing, public funding contributions, regulatory dossiers containing clinical trial data and active pharmaceutical ingredient sources, number and status of patents and patent applications, and supply chains. •Seek an agreement among EU institutions on how net prices of medical products can be publicly disclosed as part of a global effort to implement the WHA 72.8 Transparency Resolution. 2. Address market monopolies and unfair practices A strategy with more stringent and/or longer market monopolies has not served the public interest. Instead, it has undermined the financial sustainability of national health care systems and delayed access to more affordable generics and biosimilars. Data exclusivity mechanism has been proven as detrimental to access to medicines. The EU acknowledges the need to improve effective use of compulsory licenses (CL) but lack of flexibility in data exclusivity in EU legislations can hinder the efforts. The EU should: •Abolish provisions on data exclusivity, or at least introduce waivers of data and market exclusivity for effective CL when used by EU member states. •Stop the proliferation of extending monopolies through non-patent rules, including the granting of supplementary protection certificates. •Review the impact of evergreening patenting practices on access to medicines. •Address abusive pricing practices on patented products through competition law. •Support countries to improve national legislation to effectively use CL on pharmaceuticals. 3. Align EU R&D policies to access ambitions Since the European public sector is a significant global funder of biomedical R&D and a major buyer of originator products, exploring avenues to leverage public funds for more affordable access to products is strategic from economic and health perspectives. The EU should be a responsible investor to address unmet health needs globally. As demonstrated by the looming antimicrobial resistance crisis and the pandemic, addressing global health needs is in the EU’s interest. Antibiotic resistance R&D funding has largely been shaped by national interests and priorities, entrenching siloed efforts, duplication and wasted resources. The introduction of additional exclusive rights will not adequately address the urgent need for sustainable replenishment of the antibiotic pipeline. Global coordination and tailored collaborative support across stakeholders, with stewardship measures and access conditionalities introduced early into R&D processes is a prerequisite to meaningful advances in antibiotic R&D. Such models of public-led R&D already exist. The EU should: •Ensure full transparency and accountability of R&D agreements signed by the EU. •Attach concrete and enforceable access provisions to R&D investments, enabling public control over IP, data, production, supply and price of the end product. •Commission and publish a study on how upstream and downstream R&D investments can be used more effectively to enforce such public control. •Support international collaborative R&D efforts, including upstream basic research and independent downstream clinical trials. •Support long-term public investments in pandemic preparedness vaccine development under HERA.
Read full response

Meeting with Ylva Johansson (Commissioner) and

29 Mar 2021 · Migration management on Lesvos

Meeting with Kim-Tobias Eling (Cabinet of Commissioner Janez Lenarčič) and Voluntary Organisations in Cooperation in Emergencies

11 Feb 2021 · EU humanitarian aid in the context of Covid-19

Meeting with Ylva Johansson (Commissioner) and

26 Jan 2021 · European Pact on Migration and Asylum.

Meeting with Kim-Tobias Eling (Cabinet of Commissioner Janez Lenarčič)

17 Dec 2020 · Covid-19 – humanitarian response and vaccines

Meeting with Alexandra Cupsan-Catalin (Cabinet of Commissioner Ylva Johansson), Raül Hernández Sagrera (Cabinet of Commissioner Ylva Johansson)

15 Dec 2020 · VTC: New Pact on Migration and Asylum

Meeting with Pascal Canfin (Member of the European Parliament)

21 Sept 2020 · Vaccins

Meeting with Astrid Dentler (Cabinet of Vice-President Dubravka Šuica)

31 Aug 2020 · Green Paper on Ageing Rights and autonomy of the elderly Situation in care homes for elderly during the COVID-19 pandemic

Response to Intellectual Property Action Plan

14 Aug 2020

Médecins Sans Frontières feedback on the European Commission’s roadmap for an Intellectual Property Action Plan The European Commission (EC) roadmap for an intellectual property (IP) action plan lays out the need for a well-calibrated and balanced IP policy, yet it fails to recognise that granting more exclusive rights does not necessarily lead to more innovation but unambiguously discourages it. MSF has witnessed first-hand how monopolies granted to pharmaceutical corporations result in high prices negatively impacting patient access in different countries. Patents can be a barrier for the development of new medical tools showcased by IP disputes against Moderna and Inovio stalling the development of much-needed COVID-19 vaccine candidates. Overly general language concerning the scope of the inventions in patent claims obstructs research efforts for medical tools. The European Patent Office (EPO) has granted such broad patents despite their unmerited legal and scientific basis. Prolonged market monopolies on medical tools through patent evergreening undermine the fiscal sustainability of national healthcare systems. Unacceptably, the EC has not delivered a study on the impact of Supplementary Protection Certificates (SPCs) on access to medicines requested by the EC Council. Our analysis shows that SPCs upset the balance between commercial and public interests. Pharmaceutical companies do not need SPCs to recoup investments on research and development (R&D) as claimed. SPCs consistently prolong market exclusivity and delay the availability of affordable generic medicines in Europe, potentially causing unnecessary suffering or death for patients. This calls for a more fundamental review rather than a consolidation of the SPC system in Europe. Even in case of a health emergency, European Union (EU) law fails to provide safeguards to waive data exclusivity and market protections to allow effective use of compulsory licensing. EU member states also declared themselves not eligible as importers for TRIPS Article 31bis hampering effective use of compulsory licensing. The COVID-19 pandemic highlights how IP and other exclusivities are an impediment to accessing treatments, diagnostics and vaccines. A growing number of countries, including EU member states, are prepared to overcome monopoly control over medical tools to address the pandemic, an effort that should be supported by the EC. MSF strongly supports mandatory open sharing of technologies for COVID-19 related health technologies, knowledge and data, to boost the R&D of new medical tools, and expand and diversify production and supply capacities by enabling multiple manufacturers to produce. However, IP is a key challenge to this end. MSF produced a briefing document on overcoming IP monopolies to enable the sharing of COVID-19 technologies, knowledge and data. Stringent IP enforcement measures and insufficient safeguards threaten or delay the availability of treatments and vaccines. Recommendations for law and policy reform need to be incorporated into the IP action plan to address the pandemic and beyond, such as: - introduce a waiver for data exclusivity to ensure effective compulsory licensing in the EU and encourage the EU member states to restate the eligibility for import under Article 31bis of the TRIPS Agreement - raise the bar on patent quality at EPO to counter the granting of unmerited patents - stop the proliferation of secondary patents and evergreening practices - end the imposition of the EU’s Intellectual Property Rights (IPR) system to trading partners and developing countries - commission an independent study of the impact of the SPC system on access to medicines as part of a legislative review of the SPC system - map EU IP and legal barriers to the global sharing of COVID-19 technologies, knowledge and data; and develop a roadmap to enable a global right to use and produce essential COVID-19 technologies [fully referenced version attached]
Read full response

Meeting with Kurt Vandenberghe (Cabinet of President Ursula von der Leyen)

12 Jun 2020 · COVID-19

Meeting with Jutta Urpilainen (Commissioner) and OXFAM INTERNATIONAL EU ADVOCACY OFFICE and

28 May 2020 · Roundtable with Civil Society (NGOs)-The EU global response to COVID-19

Meeting with Janez Lenarčič (Commissioner) and

26 May 2020 · International humanitarian law (IHL) and MSF's key priorities linked to Covid-19

Meeting with Ylva Johansson (Commissioner) and

5 May 2020 · Migrants’ challenges in the current COVID-19 crisis and their contribution to economic recovery

Meeting with Kim-Tobias Eling (Cabinet of Commissioner Janez Lenarčič), Roland Sourd (Cabinet of Commissioner Janez Lenarčič) and Norwegian Refugee Council Europe

2 Apr 2020 · Humanitarian assistance in the context of Covid-19

Meeting with Kim-Tobias Eling (Cabinet of Commissioner Janez Lenarčič)

27 Mar 2020 · Covid-19

Meeting with Kim-Tobias Eling (Cabinet of Commissioner Janez Lenarčič)

21 Mar 2020 · Covid-19

Meeting with Ylva Johansson (Commissioner) and

12 Mar 2020 · Discussion on the current situation in Greece

Meeting with Natasha Bertaud (Cabinet of Vice-President Margaritis Schinas)

9 Mar 2020 · New Pact for Migration and Asylum, Search and Rescue, Facilitators directive

Meeting with Ylva Johansson (Commissioner) and

14 Feb 2020 · Consultations on the New Pact on Migrations

Meeting with Kim-Tobias Eling (Cabinet of Commissioner Janez Lenarčič)

14 Jan 2020 · Humanitarian aid / International Humanitarian Law

Meeting with Maria Asenius (Cabinet of Vice-President Cecilia Malmström), Pedro Velasco Martins (Cabinet of Vice-President Cecilia Malmström)

22 Jun 2018 · EU-India negotiations + trade with medicines in that context

Meeting with Giulio Di Blasi (Cabinet of High Representative / Vice-President Federica Mogherini), Michael Curtis (Cabinet of High Representative / Vice-President Federica Mogherini)

20 Apr 2018 · Migration- Mediterranean

Meeting with Giulio Di Blasi (Cabinet of High Representative / Vice-President Federica Mogherini)

12 Jan 2018 · migration

Meeting with Lowri Evans (Director-General Internal Market, Industry, Entrepreneurship and SMEs)

27 Sept 2017 · Discussion of supplementary protection certificates for medicinal products in the EU